ZA200103795B - Nitrogen containing heterobicycles as a factor Xa inhibitors. - Google Patents

Nitrogen containing heterobicycles as a factor Xa inhibitors. Download PDF

Info

Publication number: ZA200103795B
Authority: ZA; South Africa
Prior art keywords: biphen; phenyl; tetrahydropyrazolo; trifluoromethyl; aminobenzisoxazol
Prior art date: 1998-12-23

Application number

ZA200103795A

Other languages

English (en)

Inventor

John M Fevig

Joseph Cacciola

Charles G Clark

Patrick Yuk Sun Lam

Donald J P Pinto

James R Pruitt

Karen A Rossi

Qui Han

Mimi L Quan

Original Assignee

Du Pont Pharm Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

2001-05-10

Publication date

2002-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200103795(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-10 Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co

2002-08-12 Publication of ZA200103795B publication Critical patent/ZA200103795B/en

Links

QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims description 9
229940123583 Factor Xa inhibitor Drugs 0.000 title description 5
-1 methylenedioxy Chemical group 0.000 claims description 83
150000001875 compounds Chemical class 0.000 claims description 72
125000000217 alkyl group Chemical group 0.000 claims description 69
229910052757 nitrogen Inorganic materials 0.000 claims description 64
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 61
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
229910052717 sulfur Inorganic materials 0.000 claims description 25
125000005842 heteroatom Chemical group 0.000 claims description 24
229910052760 oxygen Inorganic materials 0.000 claims description 24
102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 claims description 19
108091008646 testicular receptors Proteins 0.000 claims description 19
125000002837 carbocyclic group Chemical group 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 16
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
108020002076 NR2 subfamily Proteins 0.000 claims description 14
125000004076 pyridyl group Chemical group 0.000 claims description 12
125000000623 heterocyclic group Chemical group 0.000 claims description 11
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 8
108020000002 NR3 subfamily Proteins 0.000 claims description 8
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
125000002883 imidazolyl group Chemical group 0.000 claims description 8
108020004021 3-ketosteroid receptors Proteins 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
230000009424 thromboembolic effect Effects 0.000 claims description 5
125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 4
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 4
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 4
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
125000002541 furyl group Chemical group 0.000 claims description 4
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000002757 morpholinyl group Chemical group 0.000 claims description 4
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
125000002971 oxazolyl group Chemical group 0.000 claims description 4
125000004193 piperazinyl group Chemical group 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
125000003373 pyrazinyl group Chemical group 0.000 claims description 4
125000003226 pyrazolyl group Chemical group 0.000 claims description 4
125000002098 pyridazinyl group Chemical group 0.000 claims description 4
125000000168 pyrrolyl group Chemical group 0.000 claims description 4
125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
125000000335 thiazolyl group Chemical group 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
125000001425 triazolyl group Chemical group 0.000 claims description 4
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 3
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 3
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
125000001786 isothiazolyl group Chemical group 0.000 claims description 3
125000000842 isoxazolyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 2
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000003971 isoxazolinyl group Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
125000004433 nitrogen atom Chemical group N* 0.000 claims 4
XZMVYWXGZUMIFK-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one Chemical compound O=C1NCCC2=C1NN=C2 XZMVYWXGZUMIFK-UHFFFAOYSA-N 0.000 claims 3
125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
YKPQUSLRUFLVDA-UHFFFAOYSA-N $l^{2}-azanylmethane Chemical compound [NH]C YKPQUSLRUFLVDA-UHFFFAOYSA-N 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 claims 1
229910014084 Na—B Inorganic materials 0.000 claims 1
102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 claims 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
125000005438 isoindazolyl group Chemical group 0.000 claims 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 claims 1
238000001783 near-resonance Rayleigh scattering spectroscopy Methods 0.000 claims 1
125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 claims 1
108010074860 Factor Xa Proteins 0.000 description 9
239000003112 inhibitor Substances 0.000 description 5
108090000190 Thrombin Proteins 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
238000000034 method Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102100030482 Hypoxia-inducible factor 3-alpha Human genes 0.000 description 1
101710083143 Hypoxia-inducible factor 3-alpha Proteins 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
241000232219 Platanista Species 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127090 anticoagulant agent Drugs 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
108010014806 prothrombinase complex Proteins 0.000 description 1
150000003235 pyrrolidines Chemical group 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
108010036927 trypsin-like serine protease Proteins 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200103795A 1998-12-23 2001-05-10 Nitrogen containing heterobicycles as a factor Xa inhibitors. ZA200103795B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11362898P	1998-12-23	1998-12-23
US12763399P	1999-04-02	1999-04-02

Publications (1)

Publication Number	Publication Date
ZA200103795B true ZA200103795B (en)	2002-08-12

Family

ID=26811284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200103795A ZA200103795B (en)	1998-12-23	2001-05-10	Nitrogen containing heterobicycles as a factor Xa inhibitors.

Country Status (26)

Country	Link
US (2)	US6413980B1 (es)
EP (1)	EP1140941B1 (es)
JP (1)	JP2002533465A (es)
KR (1)	KR100628407B1 (es)
CN (1)	CN100340559C (es)
AR (1)	AR024242A1 (es)
AT (1)	ATE280171T1 (es)
AU (1)	AU759711B2 (es)
BR (1)	BR9917080A (es)
CA (1)	CA2349330C (es)
DE (1)	DE69921358T2 (es)
DK (1)	DK1140941T3 (es)
EA (1)	EA004515B1 (es)
ES (1)	ES2232202T3 (es)
HK (1)	HK1052508B (es)
HR (1)	HRP990396A2 (es)
IL (2)	IL142959A0 (es)
MX (1)	MXPA01006502A (es)
MY (1)	MY138239A (es)
NO (1)	NO319816B1 (es)
NZ (1)	NZ511674A (es)
PT (1)	PT1140941E (es)
SI (1)	SI1140941T1 (es)
TW (1)	TWI225862B (es)
WO (1)	WO2000039131A1 (es)
ZA (1)	ZA200103795B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050026811A1 (en) *	2003-05-20	2005-02-03	Mjalli Adnan M. M.	Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
AU2001268712A1 (en) *	2000-06-23	2002-01-08	Bristol-Myers Squibb Company	1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors
US20040077605A1 (en) *	2001-06-20	2004-04-22	Salvati Mark E.	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en)	2000-09-19	2007-11-28	Bristol-Myers Squibb Company	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en)	2001-02-27	2004-05-06	Salvati Mark E.	Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6960595B2 (en) *	2001-03-23	2005-11-01	Bristol-Myers Squibb Pharma Company	5-6 to 5-7 Heterobicycles as factor Xa inhibitors
CA2441772A1 (en) *	2001-04-18	2002-10-31	Bristol-Myers Squibb Company	1,4,5,6-tetrahydropyrazolo-¬3,4-c\|-pyridin-7-ones as factor xa inhibitors
EP1379245A4 (en)	2001-04-18	2006-07-26	Bristol Myers Squibb Co	1, 4, 5, 6-TETRAHYDROPYRAZOLO- 3, 4-C-PYRIDINE-7-ONE AS FACTOR XA HEMMER
CA2447488A1 (en) *	2001-05-22	2002-11-28	Irina Jacobson	Bicyclic inhibitors of factor xa
ATE439360T1 (de) *	2001-09-21	2009-08-15	Bristol Myers Squibb Co	Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
TWI331526B (en)	2001-09-21	2010-10-11	Bristol Myers Squibb Pharma Co	Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003048081A2 (en)	2001-12-04	2003-06-12	Bristol-Myers Squibb Company	Glycinamides as factor xa inhibitors
TW200302225A (en)	2001-12-04	2003-08-01	Bristol Myers Squibb Co	Substituted amino methyl factor Xa inhibitors
TW200303201A (en) *	2001-12-10	2003-09-01	Bristol Myers Squibb Co	Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
AU2002364082A1 (en) *	2001-12-19	2003-07-09	Bristol-Myers Squibb Company	Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
EP1569912B1 (en)	2002-12-03	2015-04-29	Pharmacyclics, Inc.	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
CA2476594C (en) *	2002-03-05	2012-10-09	Transtech Pharma, Inc.	Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US7312214B2 (en)	2002-05-10	2007-12-25	Bristol-Myers Squibb Company	1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
EP1479678A1 (en) *	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Pyrazole-derivatives as factor xa inhibitors
CA2511321A1 (en) *	2002-12-23	2004-07-08	Aventis Pharma Deutschland Gmbh	Pyrazole-derivatives as factor xa inhibitors
US7429581B2 (en)	2002-12-23	2008-09-30	Sanofi-Aventis Deutschland Gmbh	Pyrazole-derivatives as factor Xa inhibitors
US7135469B2 (en) *	2003-03-18	2006-11-14	Bristol Myers Squibb, Co.	Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7122557B2 (en) *	2003-03-18	2006-10-17	Bristol-Myers Squibb Company	Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1479675A1 (en) *	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Indazole-derivatives as factor Xa inhibitors
US7022850B2 (en)	2003-05-22	2006-04-04	Bristol-Myers Squibb Co.	Bicyclicpyrimidones and their use to treat diseases
AU2004276341B2 (en)	2003-09-23	2011-04-14	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors
HUE026253T2 (en)	2004-02-24	2016-06-28	Sumitomo Chemical Co	Insecticidal preparations
MX2007001953A (es)	2004-08-18	2007-05-09	Astrazeneca Ab	Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
US20060069085A1 (en) *	2004-09-28	2006-03-30	Rulin Zhao	Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7381732B2 (en)	2004-10-26	2008-06-03	Bristol-Myers Squibb Company	Pyrazolobenzamides and derivatives as factor Xa inhibitors
KR20140018997A (ko)	2005-01-07	2014-02-13	신타 파마슈티칼스 코프.	염증 및 면역 관련 용도를 위한 화합물
JP2010509392A (ja) *	2006-11-13	2010-03-25	ファイザー・プロダクツ・インク	ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
WO2008133127A1 (ja)	2007-04-18	2008-11-06	Kissei Pharmaceutical Co., Ltd.	縮合へテロ環誘導体、それを含有する医薬組成物及びその医薬用途
WO2008133128A1 (ja)	2007-04-18	2008-11-06	Kissei Pharmaceutical Co., Ltd.	縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
ES2467923T3 (es)	2009-09-30	2014-06-13	Transtech Pharma, Llc	Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
LT3246021T (lt)	2010-02-25	2020-02-10	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Apiksabano kompozicijos
EP2718262B1 (en)	2011-06-10	2016-08-03	Dipharma Francis S.r.l.	Apixaban preparation process
CN104109165A (zh) *	2013-04-19	2014-10-22	四川海思科制药有限公司	4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CN103992310B (zh) *	2013-05-14	2016-07-06	中国医学科学院医药生物技术研究所	一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
CN104395312B (zh) *	2013-06-21	2016-04-27	四川海思科制药有限公司	4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用
WO2015004028A1 (de)	2013-07-08	2015-01-15	Bayer Cropscience Ag	Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
WO2015081901A1 (zh) *	2013-12-06	2015-06-11	四川海思科制药有限公司	取代的4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物及应用
WO2015162551A1 (en)	2014-04-21	2015-10-29	Mylan Laboratories Ltd	Process for the preparation of apixaban
EP3147283B1 (en) *	2014-05-22	2022-08-17	North China Pharmaceutical Company., Ltd.	Hydrazine compound as blood coagulation factor xa inhibitor
CN105085515B (zh) *	2014-05-22	2019-02-01	华北制药股份有限公司	作为凝血因子Xa抑制剂的酰肼类化合物
ES2800948T3 (es) *	2014-09-02	2021-01-05	Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd	Derivados de pirazolo[3,4-c]piridina
ES2881373T3 (es)	2014-09-05	2021-11-29	Unichem Lab Ltd	Un procedimiento mejorado para la preparación de apixabán e intermedios del mismo
CN104277037B (zh) *	2014-09-19	2015-12-09	广东东阳光药业有限公司	含有螺环的吡唑并哌啶酮类化合物及其组合物及用途
CN104277039B (zh) *	2014-09-19	2016-06-01	广东东阳光药业有限公司	含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311557B (zh) *	2014-09-19	2016-01-06	广东东阳光药业有限公司	含有二酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311575B (zh) *	2014-09-19	2016-04-20	广东东阳光药业有限公司	含有稠环的吡唑并哌啶酮类化合物及其组合物及用途
CN104311556B (zh) *	2014-09-19	2016-06-01	广东东阳光药业有限公司	含有环氧烷基取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311555B (zh) *	2014-09-19	2016-04-20	广东东阳光药业有限公司	吡唑并哌啶酮类化合物及其组合物及用途
CN104311574B (zh) *	2014-09-19	2016-04-20	广东东阳光药业有限公司	含有噻唑的吡唑并哌啶酮类化合物及其组合物及用途
CN104530029B (zh) *	2014-12-09	2017-04-12	广东东阳光药业有限公司	作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104513239B (zh) *	2014-12-10	2017-08-22	沈阳药科大学	吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
US10077263B2 (en)	2016-04-29	2018-09-18	Optimus Drugs Private Limited	Process for the preparation of Apixaban
EP3582777A4 (en)	2017-02-17	2020-12-23	Unichem Laboratories Ltd	PHARMACEUTICAL COMPOSITION OF APIXABAN
CN107235986B (zh) *	2017-05-27	2019-04-12	华南师范大学	一种合成氮氧杂桥联唑啉化合物的方法
GB201807014D0 (en)	2018-04-30	2018-06-13	Univ Leeds Innovations Ltd	Factor xlla inhibitors
AU2019339777B2 (en)	2018-09-12	2022-09-01	Novartis Ag	Antiviral pyridopyrazinedione compounds
KR102128509B1 (ko) *	2018-12-19	2020-07-01	한국과학기술연구원	말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
AU2020353055B2 (en)	2019-09-26	2024-03-07	Gilead Sciences, Inc.	Antiviral pyrazolopyridinone compounds
GB202107722D0 (en)	2021-05-28	2021-07-14	Lunac Therapeutics Ltd	Factor XIIA Inhibitors
AR127646A1 (es)	2021-11-12	2024-02-14	Insilico Medicine Ip Ltd	Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
CN113956248B (zh) *	2021-11-12	2023-07-04	贵州中医药大学	一种具有抗炎作用的化合物衍生物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3365459A (en) *	1964-09-08	1968-01-23	Ciba Geigy Corp	Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3340269A (en) *	1964-09-08	1967-09-05	Ciba Geigy Corp	1-substituted 4-acyl-2, 3-dioxo-piperidine
US3423414A (en) *	1966-01-13	1969-01-21	Ciba Geigy Corp	Pyrazolopyridines
US3939161A (en) *	1973-10-29	1976-02-17	Abbott Laboratories	1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
JPS5721388A (en) *	1980-07-11	1982-02-04	Nippon Nohyaku Co Ltd	Condensed pyrazole derivative
JPS63145282A (ja) *	1986-12-08	1988-06-17	Taiyo Yakuhin Kogyo Kk	ピリダジン誘導体
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
ATE236163T1 (de) *	1991-08-07	2003-04-15	Suntory Ltd	Pyrroloazepinverbindungen
WO1994020460A1 (en)	1993-03-11	1994-09-15	Smithkline Beecham Corporation	Chemical compounds
WO1995001980A1 (en) *	1993-07-06	1995-01-19	Pfizer Inc.	Bicyclic tetrahydro pyrazolopyridines
HUT77517A (hu) *	1994-10-20	1998-05-28	Pfizer Inc.	Biciklusos tetrahidro-pirazolo-piridin-származékok, alkalmazásuk és ilyen vegyületeket tartalmazó gyógyászati készítmények
US6323201B1 (en) *	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
JP2000501105A (ja) *	1995-12-22	2000-02-02	デュポンファーマシューティカルズカンパニー	新規なインテグリン受容体アンタゴニスト
ATE227293T1 (de) *	1996-05-15	2002-11-15	Pfizer	2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
FR2750862B1 (fr) *	1996-07-12	1998-10-16	Dupin Jean Pierre	Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
JP2002507996A (ja) *	1997-07-03	2002-03-12	デュポンファーマシューティカルズカンパニー	神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
WO1999050255A2 (en) *	1998-03-27	1999-10-07	Du Pont Pharmaceuticals Company	Disubstituted pyrazolines and triazolines as factor xa inhibitors
DE19845153A1 (de)	1998-10-01	2000-04-06	Merck Patent Gmbh	Imidazo[4,5]-pyridin-4-on-derivate
DE19900471A1 (de)	1999-01-08	2000-07-13	Merck Patent Gmbh	Imidazo[4,5c]-pyridin-4-on-derivate
JP2003509412A (ja)	1999-09-17	2003-03-11	シーオーアールセラピューティクスインコーポレイテッド	Ｘａ因子阻害剤

1999
- 1999-12-17 ES ES99967444T patent/ES2232202T3/es not_active Expired - Lifetime
- 1999-12-17 CN CNB998147710A patent/CN100340559C/zh not_active Expired - Fee Related
- 1999-12-17 IL IL14295999A patent/IL142959A0/xx unknown
- 1999-12-17 AU AU23717/00A patent/AU759711B2/en active Active
- 1999-12-17 PT PT99967444T patent/PT1140941E/pt unknown
- 1999-12-17 EP EP99967444A patent/EP1140941B1/en not_active Expired - Lifetime
- 1999-12-17 EA EA200100688A patent/EA004515B1/ru not_active IP Right Cessation
- 1999-12-17 AT AT99967444T patent/ATE280171T1/de active
- 1999-12-17 JP JP2000591042A patent/JP2002533465A/ja active Pending
- 1999-12-17 CA CA002349330A patent/CA2349330C/en not_active Expired - Lifetime
- 1999-12-17 WO PCT/US1999/030316 patent/WO2000039131A1/en active IP Right Grant
- 1999-12-17 BR BR9917080-9A patent/BR9917080A/pt not_active Application Discontinuation
- 1999-12-17 DE DE69921358T patent/DE69921358T2/de not_active Expired - Lifetime
- 1999-12-17 SI SI9930721T patent/SI1140941T1/xx unknown
- 1999-12-17 NZ NZ511674A patent/NZ511674A/en not_active IP Right Cessation
- 1999-12-17 DK DK99967444T patent/DK1140941T3/da active
- 1999-12-17 MX MXPA01006502A patent/MXPA01006502A/es active IP Right Grant
- 1999-12-17 KR KR1020017007991A patent/KR100628407B1/ko not_active IP Right Cessation
- 1999-12-21 HR HR990396A patent/HRP990396A2/hr not_active Application Discontinuation
- 1999-12-22 US US09/470,326 patent/US6413980B1/en not_active Expired - Lifetime
- 1999-12-22 MY MYPI99005666A patent/MY138239A/en unknown
- 1999-12-23 AR ARP990106759A patent/AR024242A1/es active IP Right Grant
2000
- 2000-01-15 TW TW088122748A patent/TWI225862B/zh not_active IP Right Cessation
2001
- 2001-05-03 IL IL142959A patent/IL142959A/en not_active IP Right Cessation
- 2001-05-10 ZA ZA200103795A patent/ZA200103795B/en unknown
- 2001-06-20 NO NO20013072A patent/NO319816B1/no not_active IP Right Cessation
- 2001-07-03 US US09/898,279 patent/US6673810B2/en not_active Expired - Lifetime
2003
- 2003-07-04 HK HK03104763.4A patent/HK1052508B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1052508B (zh)	2008-08-01
NZ511674A (en)	2003-11-28
JP2002533465A (ja)	2002-10-08
EP1140941A1 (en)	2001-10-10
HK1052508A1 (en)	2003-09-19
CA2349330A1 (en)	2000-07-06
CN100340559C (zh)	2007-10-03
HRP990396A2 (en)	2000-08-31
ATE280171T1 (de)	2004-11-15
NO20013072L (no)	2001-06-20
MXPA01006502A (es)	2002-04-08
IL142959A0 (en)	2002-04-21
AU2371700A (en)	2000-07-31
AR024242A1 (es)	2002-09-25
SI1140941T1 (en)	2005-04-30
EA200100688A1 (ru)	2001-12-24
CA2349330C (en)	2009-09-29
KR20010092754A (ko)	2001-10-26
DE69921358T2 (de)	2006-03-09
NO20013072D0 (no)	2001-06-20
AU759711B2 (en)	2003-04-17
NO319816B1 (no)	2005-09-19
ES2232202T3 (es)	2005-05-16
DE69921358D1 (de)	2004-11-25
TWI225862B (en)	2005-01-01
BR9917080A (pt)	2002-03-12
US6673810B2 (en)	2004-01-06
US20030004167A1 (en)	2003-01-02
DK1140941T3 (da)	2005-02-14
EA004515B1 (ru)	2004-04-29
WO2000039131A1 (en)	2000-07-06
KR100628407B1 (ko)	2006-09-26
PT1140941E (pt)	2005-02-28
CN1391575A (zh)	2003-01-15
US6413980B1 (en)	2002-07-02
IL142959A (en)	2010-05-31
MY138239A (en)	2009-05-29
EP1140941B1 (en)	2004-10-20

Publication	Publication Date	Title
ZA200103795B (en)	2002-08-12	Nitrogen containing heterobicycles as a factor Xa inhibitors.
EP3728188B1 (en)	2023-10-11	Aryl and heteroaryl substituted indole compounds
ES2834027T3 (es)	2021-06-16	Compuestos de N-pirrolidinil, N'-pirazolil-urea como inhibidores de TrkA quinasa
EP3313844B1 (en)	2020-08-26	Heteroaryl substituted aminopyridine compounds
ES2745525T3 (es)	2020-03-02	Compuestos de aminopiridina sustituida con heteroarilo
JP2022516469A (ja)	2022-02-28	ユビキチン特異的プロテアーゼ１を阻害するための組成物
KR20200101402A (ko)	2020-08-27	Tlr 억제제로서 유용한 치환된 인돌 화합물
JP2018104463A (ja)	2018-07-05	メタロ−β−ラクタマーゼ阻害剤としての３−テトラゾリル−ベンゼン−１，２−ジスルホンアミド誘導体
TW201514145A (zh)	2015-04-16	作為ｂｔｋ抑制劑的初級甲醯胺
CA2953798A1 (en)	2016-01-14	Aminopyridazinone compounds as protein kinase inhibitors
EP4038059B1 (en)	2023-09-20	Substituted carbazole compounds
AU2015291478B2 (en)	2019-04-04	Novel substituted pyrimidine compounds
CZ37494A3 (en)	1994-12-15	Cyclic derivatives, medicament containing thereof and process of their preparation
JP6843767B2 (ja)	2021-03-17	抗がん剤としての三環式化合物
TW201838981A (zh)	2018-11-01	嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
CA2979024C (en)	2024-02-20	Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
KR20140037821A (ko)	2014-03-27	히스톤 데아세틸라제 억제제 및 그의 조성물 및 사용 방법
WO2016064957A1 (en)	2016-04-28	Bicyclic heteroaryl amine compounds as pi3k inhibitors
KR20220118525A (ko)	2022-08-25	벤즈이미다졸 유도체
EP3229801B1 (en)	2020-04-01	Factor ixa inhibitors
KR20210080462A (ko)	2021-06-30	치환된 인돌 이량체 화합물
JP2022541522A (ja)	2022-09-26	Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物
JP2022501391A (ja)	2022-01-06	細菌感染症の治療及び予防のための、置換ピリドインドール
CA3185597A1 (en)	2022-01-13	Plasma kallikrein inhibitors
EP4100408B1 (en)	2024-02-28	Tricyclic heteroaryl compounds useful as irak4 inhibitors